keyword
pneumonia
hematopoiet
cell
transplant
hematolog
malign
commun
respiratori
viru
infect
cytomegaloviru
viral
pneumonia
common
pulmonari
complic
patient
hcthm
associ
high
morbid
mortal
nonspecif
imag
find
high
rate
coinfect
viral
bacteri
fungal
pathogen
microbiolog
diagnosi
gener
requir
bronchoalveolar
lavag
sampl
sent
cultur
direct
fluoresc
antibodi
nucleic
acid
test
avail
cmv
remain
common
caus
viral
pneumonia
hcthm
adopt
preemptiv
therapi
strategi
chang
transplant
techniqu
last
decad
result
signific
improv
incid
mortal
associ
cmv
pneumonia
commun
respiratori
viru
crv
infect
influenza
parainfluenza
respiratori
syncyti
viru
common
fewer
patient
develop
lower
tract
diseas
howev
establish
mortal
rate
high
infect
prevent
practic
commun
health
care
set
critic
limit
acquisit
spread
crv
highli
suscept
patient
popul
present
sign
symptom
viral
pneumonia
variabl
patient
fever
cough
hypoxia
increas
work
breath
vari
degre
depend
extent
infect
upper
respiratori
tract
infect
symptom
nasal
congest
rhinorrhea
sinus
myalgia
fatigu
may
present
infect
caus
commun
respiratori
virus
crv
patient
undergo
hematopoiet
cell
transplant
hct
treatment
hematolog
malign
hm
profound
impair
cellmedi
humor
immun
risk
lower
respiratori
tract
infect
reactiv
latent
infect
cytomegaloviru
cmv
progress
communityacquir
upper
respiratori
tract
infect
respiratori
syncyti
viru
rsv
influenza
b
clinic
present
infect
vari
diagnosi
often
complic
high
rate
coinfect
bacteri
fungal
viral
pathogen
tabl
articl
review
epidemiolog
major
viral
pathogen
pneumonia
patient
hcthm
discuss
evidencebas
prevent
strategi
treatment
comput
tomographi
ct
help
distinguish
infecti
noninfecti
caus
lung
diseas
patient
popul
also
viral
fungal
bacteri
infect
viral
pneumonia
similar
appear
ct
often
demonstr
small
centrilobular
nodul
patchi
bilater
area
ground
glass
opac
consolid
bronchial
wall
thicken
treeinbud
opac
fig
signific
bronchiol
air
trap
also
evid
diagnost
sampl
fiberopt
bronchoscopi
bronchoalveolar
lavag
predomin
sampl
method
confirm
diagnosi
viral
pneumonia
hcthm
popul
although
sampl
upper
respiratori
tract
nasopharyng
aspiratewash
may
provid
earli
identif
involv
viru
virus
sampl
lower
tract
usual
recommend
confirm
diagnosi
exclud
copathogen
risk
hemorrhag
patient
often
thrombocytopenia
endobronchi
biopsi
usual
avoid
surgic
lung
biopsi
principl
method
lung
abnorm
evalu
hct
rare
perform
standard
viral
cultur
wane
util
diagnosi
viral
pneumonia
take
week
becom
posit
sever
recent
identifi
respiratori
virus
human
metapneumoviru
coronavirus
bocaviru
notori
difficult
isol
cultur
viral
pathogen
molecular
method
viral
detect
direct
indirect
fluoresc
antibodi
test
nucleic
acid
test
use
give
reliabl
result
rapid
turnaround
time
multiplex
polymeras
chain
reaction
pcr
panel
advantag
abl
test
multipl
virus
time
sensit
fluoresc
antibodi
test
diagnosi
cmv
pneumonia
howev
continu
reli
use
standard
viral
shell
vial
cultur
histopatholog
immunohistochem
test
assumpt
cmv
pcr
test
would
sensit
low
posit
predict
valu
cmv
pneumon
howev
oper
advantag
pcr
test
much
faster
turnaround
time
effort
underway
estim
quantit
cmv
viral
load
threshold
would
predict
cmv
pneumon
rather
asymptomat
shed
cmv
common
caus
viral
pneumonia
allogen
hct
earli
report
indic
incid
associ
mortal
develop
ganciclovir
result
signific
improv
mortal
associ
cmv
pneumonia
mortal
rate
still
focu
shift
prevent
diseas
use
ganciclovir
prophylaxi
decreas
incid
pneumon
cmv
endorgan
diseas
associ
increas
rate
neutropenia
lateoccur
diseas
ie
day
posttranspl
current
era
preemptiv
therapi
patient
monitor
cmv
replic
either
antigen
cmv
dna
pcr
blood
plasma
antivir
treatment
initi
develop
cmv
pneumonia
incid
cmv
pneumonia
earli
posttranspl
period
day
posttranspl
addit
patient
develop
cmv
pneumonia
within
first
year
transplant
risk
factor
develop
cmv
pneumonia
allogen
hct
cmv
seroposit
recipi
cord
blood
graft
hlamismatch
donor
myeloabl
condit
regimen
acut
chronic
graftversushost
diseas
gvhd
use
tcelldeplet
stem
cell
cmv
pneumonia
much
less
common
patient
receiv
autolog
transplant
patient
receiv
treatment
hm
incid
report
absenc
surveil
preemptiv
therapi
treatment
ganciclovir
mgkg
intraven
iv
everi
hour
remain
firstlin
treatment
cmv
pneumon
base
result
three
nonrandom
studi
cmv
immunoglobulin
often
recommend
adjunct
treatment
howev
recent
analys
call
question
addit
benefit
therapi
durat
treatment
gener
induct
therapi
day
follow
day
mainten
therapi
ganciclovir
mgkg
iv
everi
hour
foscarnet
mgkg
iv
everi
hour
may
use
set
neutropenia
associ
less
bone
marrow
suppress
ganciclovir
commonli
caus
signific
nephrotox
antivir
resist
mutat
identifi
viral
encod
kinas
requir
ganciclovir
viral
dna
polymeras
target
ganciclovir
foscarnet
cidofovir
fortun
antivir
resist
rare
occurr
patient
hcthm
occur
patient
cmv
reactiv
foscarnet
cidofovir
brincidofovir
oral
nucleotid
analogu
prodrug
cidofovir
could
use
treatment
resist
cmv
caus
mutat
maribavir
letermovir
two
agent
current
undergo
clinic
trial
distinct
mechan
action
may
make
use
treatment
resist
cmv
diseas
howev
littl
known
genet
barrier
resist
reactiv
latent
varicella
zoster
viru
herp
simplex
viru
immunocompromis
patient
result
dissemin
diseas
pneumonia
signific
clinic
problem
patient
hcthm
longterm
prophylaxi
acyclovir
valacyclovir
standard
care
decad
case
still
rare
occur
patient
discontinu
acyclovir
prophylaxi
gener
respond
well
highdos
parenter
acyclovir
crv
common
caus
infect
patient
hcthm
howev
risk
pneumonia
vari
viru
type
patient
risk
factor
sever
virus
influenza
rsv
signific
season
variat
incid
wherea
other
parainfluenza
viru
piv
adenoviru
tend
caus
diseas
year
round
outbreak
oncolog
hct
hospit
ward
ambulatori
clinic
describ
mani
virus
emphas
import
infectionprevent
polici
procedur
prevent
transmiss
virus
among
highli
suscept
patient
particularli
challeng
patient
popul
prolong
viral
shed
often
last
week
month
influenza
influenza
diagnos
approxim
patient
hcthm
treatment
patient
present
respiratori
viru
symptom
progress
pneumonia
occur
patient
associ
mortal
rate
influenza
pandem
rate
pneumonia
much
higher
mortal
similar
risk
factor
develop
pneumonia
includ
lymphopenia
cellsml
neutropenia
cellsml
steroid
use
time
diagnosi
absenc
antivir
treatment
neuraminidas
inhibitor
primarili
oseltamivir
current
standard
care
influenza
treatment
postexposur
prophylaxi
oseltamivir
resist
describ
remain
uncommon
set
document
suspect
oseltamivir
resist
patient
impair
enter
absorpt
inhal
zanamivir
newli
licens
parenter
peramivir
use
season
vaccin
trival
inactiv
vaccin
recommend
health
care
worker
care
patient
hcthm
famili
member
household
contact
addit
recommend
patient
undergo
treatment
leukemia
lymphoma
vaccin
may
reduc
risk
hospit
respiratori
ill
ideal
vaccin
administ
least
week
cytotox
therapi
hct
recipi
vaccin
patient
less
month
transplant
ineffect
gener
recommend
chemoprophylaxi
exposur
recommend
patient
hct
within
year
transplant
patient
hm
chemotherapi
infect
rsv
common
influenza
occur
patient
undergo
allogen
hct
among
patient
hcthm
present
viral
respiratori
symptom
rsv
diagnos
involv
lower
respiratori
tract
occur
infect
patient
risk
factor
progress
pneumonia
includ
patient
age
allogen
hct
mismatch
unrel
donor
gvhd
myeloabl
condit
regimen
infect
less
day
posttranspl
prolong
lymphopenia
lack
ribavirinbas
therapi
rsv
pneumonia
associ
mortal
rate
treatment
inhal
ribavirin
shown
sever
retrospect
studi
associ
decreas
rate
progress
reduct
risk
mortal
rsv
infect
base
data
mani
center
use
inhal
ribavirin
g
hour
everi
hour
day
select
highrisk
patient
popul
howev
recent
increas
cost
formul
use
system
oral
parenter
ribavirin
increas
despit
pauciti
evid
support
practic
noteworthi
agent
novel
mechan
action
current
trial
oral
rsv
entri
inhibitor
nucleosid
rsv
polymeras
inhibitor
final
pneumonia
caus
rsv
associ
signific
airflow
declin
year
posttranspl
import
longterm
sequela
common
infect
unlik
influenza
rsv
piv
infect
occur
without
much
season
variat
incid
piv
infect
patient
hcthm
infect
patient
develop
pneumonia
case
caus
piv
type
death
occur
patient
develop
pneumonia
risk
factor
develop
pneumonia
includ
highdos
corticosteroid
use
lymphopenia
neutropenia
infect
occur
earli
posttransplant
presenc
copathogen
higher
acut
physiolog
chronic
health
evalu
ii
score
current
licens
treatment
piv
pneumonia
ribavirin
use
littl
note
improv
mortal
clinic
respons
investig
sialidas
fusion
protein
work
remov
sialic
acidcontain
receptor
respiratori
epitheli
cell
prevent
piv
bind
success
use
sever
case
adult
pediatr
piv
pneumonia
hcthm
current
phase
iii
clinic
trial
adenoviru
human
adenoviru
hadv
infect
caus
signific
dissemin
diseas
patient
hcthm
includ
sever
pneumonia
sever
diseas
occur
hct
especi
children
patient
hm
treat
alemtuzumab
adenoviru
infect
occur
patient
undergo
allogen
hct
case
occur
children
total
patient
develop
hadv
endorgan
diseas
lung
involv
case
infect
less
common
autolog
hct
occur
patient
endorgan
diseas
includ
pneumonia
rare
addit
tcell
deplet
risk
factor
hadv
diseas
lymphopenia
receipt
cord
blood
graft
gvhd
requir
increas
prolong
immunosuppress
absenc
hadvspecif
tcell
respons
patient
adenovir
pneumonia
often
involv
site
gut
liver
mortal
rate
dissemin
diseas
high
firstlin
treatment
hadv
diseas
includ
pneumon
cidofovir
mgkg
weekli
mgkg
three
time
weekli
reduct
immunosuppress
whenev
possibl
common
crv
human
metapneumoviru
novel
coronavirus
eg
sarscov
merscov
even
human
rhinoviru
caus
lower
respiratori
tract
infect
patient
hcthm
although
virus
specif
biolog
epidemiolog
risk
factor
pneumonia
identifi
crv
lymphopenia
infect
occur
earli
hct
share
yet
directact
treatment
virus
effort
prevent
infect
highli
immunosuppress
patient
remain
paramount
current
guidelin
recommend
prevent
contact
symptomat
health
care
worker
famili
member
daili
screen
health
care
worker
visitor
inpati
unit
symptom
activ
surveil
crv
diseas
isol
symptomat
patient
recognit
viral
shed
prolong
patient
popul
summari
profound
prolong
immunosuppress
experienc
patient
undergo
hct
intens
chemotherapi
hm
result
rate
viral
pneumonia
far
surpass
incid
gener
popul
patient
viral
pneumonia
gener
present
fever
hypoxia
often
bilater
patchi
nodular
infiltr
without
surround
ground
glass
opac
highresolut
ct
imag
imag
find
help
distinguish
among
differ
viral
etiolog
patient
commonli
viral
bacteri
fungal
coinfect
microbiolog
diagnosi
typic
requir
fiberopt
bronchoscopi
bronchoalveolar
lavag
although
cmv
remain
common
caus
viral
pneumonia
popul
effort
treat
cmv
replic
earli
cours
chang
transplant
practic
result
improv
incid
associ
mortal
cmv
pneumonia
taken
togeth
crv
infect
also
occur
commonli
patient
popul
howev
rate
progress
pneumonia
vari
depend
viru
influenza
rsv
piv
caus
lower
tract
diseas
commonli
adenoviru
human
metapneumoviru
rhinoviru
patient
risk
factor
relat
degre
immunosuppress
ie
lymphopenia
earli
posttranspl
steroid
use
establish
howev
pneumonia
caus
infect
associ
high
mortal
rate
part
lack
directact
antivir
agent
virus
infect
prevent
practic
limit
acquisit
crv
patient
hcthm
decreas
risk
spread
within
clinic
inpati
set
particular
import
